Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Can-Fite Biopharma Ltd ADR (CANF)

Can-Fite Biopharma Ltd ADR (CANF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Can-Fite BioPharma, Ltd. to Present at the LD Micro Invitational XIV Newsfile - Mon Apr 1, 6:16AM CDT

Ramat Gan, Israel--(Newsfile Corp. - April 1, 2024) - Can-Fite BioPharma, Ltd. (NYSE American: CANF) announced today that it will be presenting at The 14th Annual LD Micro Invitational at the Sofitel New...

CANF : 2.10 (+1.45%)
Happy Thanksgiving, Uncle Sam! Baystreet - Fri Nov 17, 2023

Monday U.S. Economic Lookahead U.S. leading economic indicators (Oct.) Featured Earnings Agilent ...

WN.TO : 176.00 (-0.71%)
A : 137.95 (-1.62%)
TCOM : 48.81 (-0.79%)
KEYS : 152.20 (-0.73%)
NVDA : 878.94 (+2.20%)
LOW : 229.42 (-0.26%)
MDT : 79.71 (-0.65%)
DE : 394.60 (+0.20%)
GDS : 6.21 (+1.47%)
BMA : 48.65 (+2.51%)
HTHT : 38.39 (-0.52%)
LEXX : 2.2500 (+13.07%)
All You Need to Know About Can-Fite Biopharma Ltd (CANF) Rating Upgrade to Buy Zacks - Wed May 10, 2023

Can-Fite Biopharma Ltd (CANF) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

CANF : 2.10 (+1.45%)
Author
Can-Fite BioPharma Spikes on Pancreatic Cancer Inhibition Finding MarketBeat - Tue May 2, 2023

Can-Fite BioPharma Ltd. (NYSEAMERICAN: CANF) is an Israel-based biotechnology firm that develops small-molecule therapeutic treatments for cancers

CANF : 2.10 (+1.45%)
BMY : 48.53 (+0.04%)
LLY : 749.25 (-0.20%)
MRK : 125.77 (-0.33%)
Inhibition of Pancreatic Cancer by Namodenoson: Molecular Mechanism of Action Discovered by Can-Fite Scientists Business Wire - Tue May 2, 2023

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today...

CANF : 2.10 (+1.45%)
Can-Fite Announces New Management Structure as Advanced Stage Pipeline Moves Toward Commercialization Business Wire - Mon Apr 24, 2023

Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today...

CANF : 2.10 (+1.45%)
Can-Fite: EMA Gives Green Light for Piclidenoson Pivotal Phase III Clinical Trial for Psoriasis Treatment Business Wire - Mon Apr 10, 2023

Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today...

CANF : 2.10 (+1.45%)
Can-Fite Reports 2022 Financial Results & Provides Clinical Update Business Wire - Thu Mar 30, 2023

Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today...

CANF : 2.10 (+1.45%)
Can-Fite to Conduct Meetings at the BIO-Europe Spring Conference with Pharma Companies Interested in Licensing and Distributing Piclidenoson and Namodenoson Business Wire - Thu Mar 16, 2023

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, announced today...

CFBI : 10.08 (-0.30%)
CANF : 2.10 (+1.45%)
Can-Fite to Treat Decompensated Liver Cirrhosis Patients with Namodenoson Under Compassionate Use Setting Business Wire - Mon Mar 13, 2023

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, announced today...

CFBI : 10.08 (-0.30%)
CANF : 2.10 (+1.45%)

Barchart Exclusives

2 Struggling Stocks to Buy at a Discount Barchart - 30 minutes ago
The decline in fundamentally strong stocks presents an opportunity for investors to capitalize on the future recovery. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot